Abstract:BACKGROUND Many patients report adverse reactions to, and may not tolerate, statin therapy. These patients may be at increased risk for coronary heart disease (CHD) events and mortality.OBJECTIVES This study evaluated the risk for recurrent myocardial infarction (MI), CHD events, and all-cause mortality in Medicare beneficiaries with statin intolerance and in those with high adherence to statin therapy.METHODS We studied 105,329 Medicare beneficiaries who began a moderate-or high-intensity statin dosage after hospitalization for MI between 2007 and 2013. Statin intolerance was defined as down-titrating statins and initiating ezetimibe therapy, switching from statins to ezetimibe monotherapy, having International Classification of Diseases, 9th revision, diagnostic codes for rhabdomyolysis or an antihyperlipidemic adverse event, followed by statin down-titration or discontinuation, or switching between >= 3 types of statins within 1 year after initiation. High statin adherence over the year following hospital discharge was defined as proportion of days covered >= 80%. Recurrent MI, CHD events (recurrent MI or a coronary revascularization procedure), and mortality were identified from 1 year after hospital discharge through December 2014.RESULTS Overall, 1,741 patients (1.65%) had statin intolerance, and 55,567 patients (52.8%) had high statin adherence. Over a median of 1.9 to 2.3 years of follow-up, there were 4,450 recurrent MIs, 6,250 CHD events, and 14,311 deaths. Compared to beneficiaries with high statin adherence, statin intolerance was associated with a 36% higher rate of recurrent MI (41.1 vs. 30.1 per 1,000 person-years, respectively), a 43% higher rate of CHD events (62.5 vs. 43.8 per 1,000 person-years, respectively), and a 15% lower rate of all-cause mortality (79.9 vs. 94.2 per 1,000 person-years, respectively). The multivariate-adjusted hazard ratios (HR) comparing beneficiaries with statin intolerance versus those with high statin adherence were 1.50 (95% confidence interval [CI]: 1.30 to 1.73) for recurrent MI, 1.51 (95% CI: 1.34 to 1.70) for CHD events, and 0.96 (95% CI: 0.87 to 1.06) for all-cause mortality.CONCLUSIONS Statin intolerance was associated with an increased risk for recurrent MI and CHD events but not all-cause mortality. (J Am Coll Cardiol 2017; 69: 1386-95) (C) 2017 by the American College of Cardiology Foundation.

Long-Term Statin Use Following Re-Initiation among Medicare Beneficiaries with Coronary Heart Disease

Statin Discontinuation, Reinitiation, and Persistence Patterns among Medicare Beneficiaries after Myocardial Infarction A Cohort Study

Healthcare Utilization and Statin Re‐Initiation among Medicare Beneficiaries with a History of Myocardial Infarction

Factors Associated with Statin Re-Initiation in Medicare Beneficiaries: A Case-Crossover Study

Intensive Versus Moderate Statin Therapy Discontinuation in Patients with Acute Ischemic Stroke or Transient Ischemic Attack.

Initiation of Statins for Primary Prevention in Heart Failure With Preserved Ejection Fraction

Long-Term Use of Statins Lowering the Risk of Rehospitalization Caused by Ischemic Stroke Among Middle-Aged Hyperlipidemic Patients: A Population-Based Study

Statin use trajectories postbariatric surgery: a matched cohort analysis

Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction.

Impact of statin adherence and interruption within 6 months after ST-segment elevation myocardial infarction (STEMI): Results from the real-world regional registry FAST-STEMI

Statin Therapy Before Transition to End-Stage Renal Disease With Posttransition Outcomes.

Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment

Associated Factors for Discontinuation of Statin Use One Year after Discharge in Patients with Acute Coronary Syndrome in China

Statin utilization and cardiovascular outcomes in a real-world primary prevention cohort of older adults

Association between statin therapy and long-term clinical outcomes in patients with stable coronary disease undergoing percutaneous coronary intervention

Prescription of Statins at Discharge and 1‐year Risk of Major Clinical Outcomes among Acute Coronary Syndromes Patients with Extremely Low LDL‐cholesterol in Clinical Pathways for Acute Coronary Syndromes Studies

Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins

Abstract WP261: Healthcare Utilization Patterns and Disparities in High Intensity Statin Use in Stroke Patients

Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings

Abstract 14720: Persistence and Adherence to Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies and Ezetimibe in Real - World Settings

The long-term clinical impact of high-intensity statin therapy in older patients with acute myocardial infarction